Substance abuse services; authorizing the possession, acquisition, distribution and administration of emergency opioid antagonists and adulterant test strips by any person. Effective date. Emergency.
SB65 creates a new section of Oklahoma law authorizing any person to possess, store, acquire, distribute, make available, and administer emergency opioid antagonists, such as naloxone, for the treatment of an opioid overdose. The bill defines “emergency opioid antagonist” and broadly defines “person” to include individuals, businesses, governmental entities, tribal entities, schools, and other legal entities.
The measure is designed to expand access to overdose-reversal medication and encourage bystanders, organizations, and institutions to keep and use these drugs in emergencies. It allows administration when a person reasonably and in good faith believes someone is experiencing an opioid overdose, and it expressly permits acquisition by purchase or donation, subject to applicable federal law.
SB65 amends Oklahoma substance abuse law by adding statutory protections for the possession, distribution, and use of emergency opioid antagonists. It provides criminal immunity for conduct covered by the bill and civil immunity for good-faith distribution, making available, or administration, except in cases of gross negligence or willful or wanton misconduct. The bill therefore reduces legal risk for individuals and organizations that stock and use naloxone and similar overdose-reversal drugs, and it is likely to affect schools, public agencies, health providers, nonprofits, businesses, and other entities that may respond to overdoses.
The bill appears to have broad bipartisan support and little visible opposition. It advanced unanimously through the Senate Public Safety Committee, passed the Senate 41-0 on third reading, cleared two House committees unanimously, and passed the House 83-2. The voting pattern suggests strong agreement that expanding access to overdose-reversal medication is a public health and safety measure.
There is little evidence of substantive controversy in the available record. The main policy issue is the scope of immunity and the breadth of who may possess, distribute, and administer emergency opioid antagonists, including non-medical actors and a wide range of institutions. Any concerns would likely center on liability, proper training, and whether the protections are too broad, but the recorded votes indicate those concerns did not generate significant opposition.